PLX2853
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PLX2853, covering 2024-11-04 to 2024-11-04. Get the full timeline:
Most recent: Clinical Trial Update: PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer [Phase 1, Phase 2]